Гормонотерапия в акушерстве и гинекологии. Иллюзии и реальность

Ryan K. J., Smith O. W. Biogenesis of estrogens by the human ovary. II. Conversion of progesterone-4-C-14 to estrone and estradiol. J. Biol. Chem., 1961; 236:710–714.

Saito S., Sakai M. Th1/Th2 balance in preeclampsia. Reprod. Immunol., 2003; 59:161–173.

Saito S. Cytokine network at the feto-maternal interface. J. Reprod. Immunol., 2000; 47:87–103.

Salafia C., et al. Placental and decidual histology in spontaneous abortion: detailed description and correlations with chromosome number. Obstet. Gynecol., 1993; 82:295–303.

Salamonsen L. A., Giudice L. C. ’The Curse’: A 21st Century Perspective of Models of Its Molecular Basis. Endocrinology, 2010; 151 (9):4092–4095.

Salamonsen L. A., et al. Production of endometrial matrix metalloproteinases but not their tissue inhibitors is modulated by progesterone withdrawal in an in vitro model for menstruation The Journal of clinical endocrinology and metabolism, 1997; 82:1409–1415.

Salamonsen L. A., Lathbury L. J. Endometrial leukocytes and menstruation. Hum. Reprod. Update, 2000; 6 (1):16–27.

Salazar E. L., Calzada L. The role of progesterone in endometrial estradiol- and progesterone-receptor synthesis in women with menstrual disorders and habitual abortion. Gynecol. Endocrinol., 2007; 23 (4):222–225.

Salazar E. L., Calzada S. L., Escontria M. Estradiol/androgen receptors during aging: microsomal distribution in human benign prostatic hypertrophy. Arch. Androl., 2005; 51:49–53.

Salazar E. L., et al. Estrogen receptor in displastic and malignant cervical tissue: expression, localisation and prognostic significance. Med. Sci. Res., 1996; 24:523–524.

Salazar E. L., Mercado E., Calzada S. L. Prostatic cancer/benign prostatic hypertrophy. Subcellular distribution of estradiol/androgen receptors. Arch. Androl., 2005; 51:135–139.

Salazar E. L., Paredes., Calzada L. Endometrial thickness of postmenopausal breast cancer patients treated with tamoxifen. Gynecol. Endocrinol., 2005; 21:312–316.

Salker M., et al. Natural selection of human embryos: impaired decidualization of the endometrium disables embryo-maternal interactions and causes recurrent pregnant loss. PLoS One, 2010; 5 (4):e10287.

Salomon L. J., et al. Changes in progesterone-induced-blocking factor expression rates following mifepristone administration in termination of pregnancy at 5 to 8 weeks. J. Matern. Fetal. Neonatal. Med., 2005; 17:353–356.

Samalecos A., Gellersen B. Systematic expression analysis and antibody screening do not support the existence of naturally occurring progesterone receptor (PR) — C, PR-M, or other truncated PR isoforms. Endocrinol., 2008; 149:5872–5887.

Sanchez-Ramos L., Kaunitz A. M., Delke I. Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials. Am. J. Obstet. Gynecol., 2005; 105:273–279.

Santen R. J., et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J. Clin. Endocrinol. Metab., 2010; 95:s1-s66.

Sarkar N. N. The state-of-the-art of emergency contraception with the cutting edge drug. German Medical Science, 2011; 9:1–7.

Sauer M. V., et al. Endometrial responses to various hormone replacement regimens in ovarian failure patients preparing for embryo donation. Int. J. Gynecol. Obstet., 1991; 35:61–68.

Savaris R. F., et al. Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles. J. Clin. Endocrinol. Metabol., 2011; 96 (6):1737–1746.

Scatchard G. The attraction of proteins for small molecules and ions. Ann. NY. Acad. Sci., 1949; 51:660–672.

Schedin P. Pregnancy-associated breast cancer and metastasis. Nat. Rev. Cancer, 2006; 6:281–291.

Schindler A. E., et al. Classification and pharmacology of progestins. Maturitas, 2003; 46 (Suppl 1):S7–S16.

Schindler A. E. Non-contraceptive benefits of hormonal contraceptives. Minerva Ginecol., 2010; 62:319–329.

Schmidt K. L., et al. Progesterone supplementation during early gestation after in vitro fertilization has no effect on the delivery rate. Fertil. Steril., 2001; 75:337–341.

Scholer H. F., de Wachter A. Evaluation of androgenic properties of progestational compounds in the rat by the female foetal masculinisation test. Acta Endocrinol. (Copenh.), 1961; 38:128–136.

Schoolcraft W., et al. Lower pregnancy rate with premature luteinisation during pituitary suppression with leuprolide acetate. Fertil. Steril., 1991; 55:563–566.

Schumacher M., et al. Genomic and membrane actions of progesterone: implications for reproductive physiology and behavior. Behav. Brain. Res., 1999; 105:37–52.

Schumacher M., et al. Progesterone and progestins: neuroprotection and myelin repair. Current Opinion in Pharmacology, 2008; 8:740–746.

Schumacher M., et al. Progesterone: Therapeutic opportunities for neuroprotection and myelin repair. Pharmacology & Therapeutics, 2007; 116:77–106.

Schwarzenbach H., et al. Stimulatory effect of progesterone on the expression of steroidogenic acute regulatory protein in MA-10 Leydig cells. Biol. Reprod., 2003; 68:1054–1063.